Holen Sie sich die Stockscreener-App
5.73
5.52%
0.30
Handel nachbörslich:
5.73
Astria Therapeutics Inc Aktie (ATXS) Neueste Nachrichten
(ATXS) Trading Report - news.stocktradersdaily.com
Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit - BioSpace
Astria Therapeutics to Participate in Upcoming Oppenheimer Innov - GuruFocus
Astria CEO Discusses Breakthrough Dermatology Treatments at Major Oppenheimer Summit - Stock Titan
HC Wainwright Reaffirms “Buy” Rating for Astria Therapeutics (NASDAQ:ATXS) - Defense World
Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Target Price at $30.00 - Defense World
Astria Therapeutics (ATXS) Receives Reiterated Buy Rating and $1 - GuruFocus
Astria Therapeutics (ATXS) Reports Promising Results for Navenib - GuruFocus
Astria Therapeutics Announces Positive Initial Results from the - GuruFocus
Astria Therapeutics Says New Data Back Navenibart Dose Regimen for Hereditary Angioedema - MarketScreener
Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress - Yahoo Finance
California State Teachers Retirement System Increases Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Two Sigma Investments LP Sells 2,042 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics Stockholders Approve Key Amendments - TipRanks
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Cantor Fitzgerald Estimates ATXS FY2026 Earnings - Defense World
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress - BioSpace
(ATXS) Investment Report - news.stocktradersdaily.com
Astria Therapeutics to Present at Upcoming European Academy of A - GuruFocus
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress | ATXS Stock News - GuruFocus
Jane Street Group LLC Has $233,000 Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
BNP Paribas Financial Markets Acquires Shares of 5,572 Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Astria Therapeutics Announces Inducement Grants Under Nasdaq Lis - GuruFocus
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ATXS Stock News - GuruFocus
ProShare Advisors LLC Invests $140,000 in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Deutsche Bank AG Buys 13,986 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Citizens JMP maintains $25 target on Astria Therapeutics stock By Investing.com - Investing.com Canada
Astria Therapeutics to Present at Upcoming Jefferies Global Healthcare Conference - Business Wire
Janus Henderson Group PLC Takes Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficien - GuruFocus
Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop | ATXS Stock News - GuruFocus
Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop - Business Wire
Northern Trust Corp Has $4.10 Million Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics to Present at Upcoming Eastern Allergy Confe - GuruFocus
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference | ATXS Stock News - GuruFocus
New Clinical Data: Astria's Navenibart Cuts Hereditary Angioedema Attack Severity, Reduces Rescue Med Usage - Stock Titan
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference - New Castle News
Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Price Target at $30.00 - Defense World
Price T Rowe Associates Inc. MD Buys 2,878 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Cantor Fitzgerald Analysts Lower Earnings Estimates for ATXS - Defense World
Wedbush Lowers Earnings Estimates for Astria Therapeutics - Defense World
Q2 EPS Estimate for Astria Therapeutics Lowered by Analyst - Defense World
Astria Therapeutics’ (ATXS) “Overweight” Rating Reiterated at Cantor Fitzgerald - Defense World
FMR LLC Reduces Holdings in Astria Therapeutics Inc - GuruFocus
(ATXS) Technical Data - news.stocktradersdaily.com
Astria Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Analysts Offer Insights on Healthcare Companies: Astria Therapeutics (ATXS), Aquestive Therapeutics (AQST) and Olema Pharmaceuticals (OLMA) - The Globe and Mail
Astria Therapeutics Reports Increased Loss Amid Rising R&D Costs - TipRanks
Analyst Reiterates Overweight Rating for ATXS with Stable Price Target | ATXS Stock News - GuruFocus
Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation - Yahoo Finance
Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update | ATXS Stock News - GuruFocus
Astria Therapeutics (ATXS) Advances Navenibart as Groundbreaking HAE Therapy | ATXS Stock News - GuruFocus
Astria Therapeutics (ATXS) Sees Price Target Adjustment Amid Ong - GuruFocus
Astria Therapeutics price target lowered to $25 from $26 at Citizens JMP - TipRanks
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):